ECSP14018630A - Formulaciones farmacéuticas novedosas - Google Patents

Formulaciones farmacéuticas novedosas

Info

Publication number
ECSP14018630A
ECSP14018630A ECIEPI201418630A ECPI201418630A ECSP14018630A EC SP14018630 A ECSP14018630 A EC SP14018630A EC IEPI201418630 A ECIEPI201418630 A EC IEPI201418630A EC PI201418630 A ECPI201418630 A EC PI201418630A EC SP14018630 A ECSP14018630 A EC SP14018630A
Authority
EC
Ecuador
Prior art keywords
particulate
metal salts
pharmaceutical formulations
novel pharmaceutical
inamide
Prior art date
Application number
ECIEPI201418630A
Other languages
English (en)
Inventor
Filip Marcel C Vanhoutte
Walter Ferdinand Maria Filliers
Carina Leys
Patrick Hubert J Nieste
Alex Herman Copmans
Rudy Laurent Maria Broeckx
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14018630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of ECSP14018630A publication Critical patent/ECSP14018630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona inter alia una formulación farmacéutica en polvo seco para inhalación que comprende: (i) 6-(2-((4-amino-3-(3-hidroxifenil)-1 H-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-clorobencil)-4-oxo-3,4-dihidroquinazolin-5-il)-N,N-bis(2-metoxietil)hex-5-inamida o una sal farmacéuticamente aceptable del mismo, incluyendo todos los estereoisómeros, tautómeros y derivados isotópicos del mismo y solvatos del mismo en forma particulada como ingrediente activo; (ii) lactosa particulada como portador; y (iii) un agente estabilizador particulado seleccionado de sales metálicas de ácido esteárico como estearato de magnesio y sales metálicas de estearil fumarato.
ECIEPI201418630A 2012-03-13 2014-09-12 Formulaciones farmacéuticas novedosas ECSP14018630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
ECSP14018630A true ECSP14018630A (es) 2015-09-30

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
ECIEPI201418142A ECSP14018142A (es) 2012-03-13 2014-09-10 Inhibidores de cinasa de fosfoinositida 3 cristalina
ECIEPI201418630A ECSP14018630A (es) 2012-03-13 2014-09-12 Formulaciones farmacéuticas novedosas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECIEPI201418142A ECSP14018142A (es) 2012-03-13 2014-09-10 Inhibidores de cinasa de fosfoinositida 3 cristalina

Country Status (36)

Country Link
US (3) US20150099768A1 (es)
EP (2) EP2834244B1 (es)
JP (3) JP2015509973A (es)
KR (2) KR20140141596A (es)
CN (2) CN104302650B (es)
AU (2) AU2013234081B2 (es)
CA (2) CA2864652A1 (es)
CL (2) CL2014002386A1 (es)
CO (2) CO7061079A2 (es)
CR (2) CR20140417A (es)
CY (1) CY1118565T1 (es)
DK (1) DK2834244T3 (es)
EA (2) EA025465B1 (es)
EC (2) ECSP14018142A (es)
ES (2) ES2650791T3 (es)
GT (2) GT201400182A (es)
HK (2) HK1203487A1 (es)
HR (1) HRP20161383T1 (es)
HU (1) HUE029420T2 (es)
IL (2) IL233886A (es)
IN (2) IN2014MN01998A (es)
LT (1) LT2834244T (es)
MX (2) MX355299B (es)
MY (1) MY171125A (es)
NI (2) NI201400101A (es)
NZ (2) NZ628072A (es)
PE (2) PE20142342A1 (es)
PH (2) PH12014501713A1 (es)
PL (1) PL2834244T3 (es)
PT (1) PT2834244T (es)
SG (2) SG11201404522VA (es)
SI (1) SI2834244T1 (es)
TW (2) TWI617561B (es)
UA (1) UA115544C2 (es)
WO (2) WO2013136076A1 (es)
ZA (2) ZA201407373B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX355299B (es) 2012-03-13 2018-04-11 Respivert Ltd Inhibidores de cinasa de fosfoinositida 3 cristalina.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
SG11201610770PA (en) 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
WO2016005443A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EP3443954A4 (en) * 2016-04-15 2019-11-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. INHALED PREPARATION OF ISOGLYCYRRIC ACID OR SALT AND USE IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US20050002930A1 (en) 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
DK2004654T3 (da) 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
CN101448505A (zh) 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
CN101495515A (zh) 2006-05-24 2009-07-29 拜耳先灵医药股份有限公司 免疫原性降低的高亲和力人及人源化抗α5β1整联蛋白功能阻断性抗体
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
JP2010526120A (ja) * 2007-05-09 2010-07-29 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc MODIFIED CHLOROQUINE WITH SINGLE RING UNIT OR CONDENSED RING UNIT
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010281265A1 (en) 2009-08-05 2012-03-22 Versitech Limited Antiviral compounds and methods of making and using thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
AU2011298315B2 (en) * 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
MX355299B (es) 2012-03-13 2018-04-11 Respivert Ltd Inhibidores de cinasa de fosfoinositida 3 cristalina.

Also Published As

Publication number Publication date
HRP20161383T1 (hr) 2016-12-02
SI2834244T1 (sl) 2016-12-30
EA023715B1 (ru) 2016-07-29
CA2864643A1 (en) 2013-09-19
NZ628072A (en) 2015-08-28
CN104284679A (zh) 2015-01-14
ES2600705T3 (es) 2017-02-10
MX355299B (es) 2018-04-11
GT201400183A (es) 2015-07-08
IL233886A (en) 2017-12-31
CL2014002386A1 (es) 2015-02-27
AU2013234081A1 (en) 2014-08-21
NZ627963A (en) 2015-08-28
CO7061079A2 (es) 2014-09-19
US9642799B2 (en) 2017-05-09
WO2013136075A1 (en) 2013-09-19
CL2014002385A1 (es) 2015-01-09
NI201400100A (es) 2015-01-12
MX2014010990A (es) 2014-10-13
CN104302650A (zh) 2015-01-21
WO2013136076A1 (en) 2013-09-19
PH12014501713A1 (en) 2014-10-13
JP2015509973A (ja) 2015-04-02
IN2014MN02000A (es) 2015-08-14
UA115544C2 (uk) 2017-11-27
LT2834244T (lt) 2016-11-10
AU2013234080A1 (en) 2014-08-21
PL2834244T3 (pl) 2017-01-31
CA2864652A1 (en) 2013-09-19
JP6189874B2 (ja) 2017-08-30
EP2834244A1 (en) 2015-02-11
DK2834244T3 (en) 2016-11-28
EA025465B1 (ru) 2016-12-30
MX357170B (es) 2018-06-27
JP2015509972A (ja) 2015-04-02
EA201491675A1 (ru) 2014-12-30
TW201350139A (zh) 2013-12-16
SG11201404519UA (en) 2014-10-30
ZA201407373B (en) 2016-10-26
TWI617561B (zh) 2018-03-11
SG11201404522VA (en) 2014-10-30
PE20142342A1 (es) 2015-01-16
ZA201407374B (en) 2016-10-26
HK1203812A1 (en) 2015-11-06
PH12014501922A1 (en) 2014-11-24
CY1118565T1 (el) 2017-07-12
NI201400101A (es) 2016-11-30
ES2650791T3 (es) 2018-01-22
EP2825202A1 (en) 2015-01-21
US20170239256A1 (en) 2017-08-24
AU2013234081B2 (en) 2017-02-02
CN104302650B (zh) 2017-07-18
ECSP14018142A (es) 2015-06-30
HUE029420T2 (en) 2017-02-28
EP2834244B1 (en) 2016-08-10
PT2834244T (pt) 2016-11-03
GT201400182A (es) 2015-09-17
EA201491674A1 (ru) 2014-12-30
PE20141964A1 (es) 2014-12-01
MX2014010991A (es) 2014-10-13
KR20140141596A (ko) 2014-12-10
IN2014MN01998A (es) 2015-08-14
US20150099768A1 (en) 2015-04-09
CR20140416A (es) 2014-10-31
CN104284679B (zh) 2017-08-04
TW201400484A (zh) 2014-01-01
MY171125A (en) 2019-09-26
US20150105408A1 (en) 2015-04-16
CO7051030A2 (es) 2014-09-10
CR20140417A (es) 2014-10-31
HK1203487A1 (zh) 2015-10-30
JP2018008992A (ja) 2018-01-18
TWI586378B (zh) 2017-06-11
KR20140131971A (ko) 2014-11-14
IL233883A0 (en) 2014-09-30
AU2013234080B2 (en) 2016-12-22
EP2825202B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
ECSP14018630A (es) Formulaciones farmacéuticas novedosas
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PE20150998A1 (es) Inhibidores de histona demetilasas
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
EP3086787A1 (en) Pharmaceutical combinations
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
UY37459A (es) Formulación liposomal
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
AR096045A1 (es) Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco
BR112017012566A2 (pt) formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
TH156275A (th) สูตรผสมทางเภสัชกรรมชนิดใหม่
TH156276A (th) ตัวยับยั้ง pi3 ไคเนสที่เป็นผลึก
TH164080B (th) รูปเเบบยาของเเข็ง
AR104452A1 (es) Combinaciones de inhibidores de irak4
CU20060219A7 (es) Formulaciones con liberación controlada de principio activo que contiene vardenafilo
CO6280050A1 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa